Montol (Montelukast)

Montelukast, the active ingredient in Montol, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is used to manage conditions mediated by cysteinyl leukotrienes, primarily within the respiratory allergy spectrum.

Asthma: reduces bronchoconstriction and airway inflammation, improving symptom control. Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergen exposure. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity, allowing better exercise tolerance.

Montelukast may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often transient. - Abdominal pain: discomfort or cramps in the stomach area. - Nausea: feeling of queasiness, sometimes leading to vomiting. - Dizziness: light‑headed sensation, especially when standing quickly. - Fatigue: unusual tiredness or lack of energy. - Cough: persistent dry cough without infection.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis requiring immediate care. - Mood changes: depression, anxiety, or suicidal thoughts. - Hepatic injury: signs of liver dysfunction such as jaundice. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Eosinophilic granulomatosis with polyangiitis: rare vasculitis affecting multiple organs. - Blood dyscrasias: unexplained bruising or bleeding abnormalities.

When prescribing Montelukast, clinicians should consider several safety aspects.

Pregnancy: consult a healthcare professional as safety data are limited. Breastfeeding: weigh potential benefits against possible infant exposure. Liver impairment: use with caution; monitor hepatic function if indicated. Concomitant phenobarbital: may reduce montelukast effectiveness. Drug interactions: review all concurrent medications for possible effects. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Montelukast can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Ritonavir: may increase montelukast plasma concentrations. - Phenobarbital: may decrease montelukast exposure, reducing therapeutic effect. - Carbamazepine: may lower montelukast levels, compromising efficacy.

Moderate Interactions (Monitor Closely): - Fluconazole: may raise montelukast concentrations, requiring observation. - Erythromycin: can increase drug levels, monitor for side effects. - Warfarin: may affect INR; regular coagulation monitoring is advised.